Corpus overview


MeSH Disease

HGNC Genes

There are no HGNC terms in the subcorpus


There are no transmission terms in the subcorpus


There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page

    ECMO Therapy for Critically Ill Coronavirus Disease MESHD Coronavirus Disease 2019 MESHD Patients in Wuhan, China: A Retrospective Multicenter Cohort Study

    Authors: Jing Fang; Yue Chen; Ming Hu; Rui Li; Juanjuan Qin; Lin Cheng; Yi He; Yi Li; Qiang Zhou; Daixing Zhou; Jun Chen; Fei Huang; Fang Lei; Bo Yang; Hongping Deng; Yufeng Yuan; Jiahong Xia; Hongliang Li; Chaolin Huang; Song Wan; Xiang Wei

    doi:10.21203/ Date: 2020-08-04 Source: ResearchSquare

    Background The coronavirus disease 2019 MESHD ( COVID-19 MESHD) pandemic has led to surges in the demand for extracorporeal membrane oxygenation (ECMO) therapy. However, little in-depth evidence is known about the application of ECMO therapy in COVID-19 MESHD patients.Methods This retrospective multicenter cohort study included 88 patients who had been diagnosed with COVID-19 MESHD and received ECMO therapy at seven designated hospitals in Wuhan, China. The clinical characteristics, laboratory examinations, treatments, and outcomes were extracted from electronic medical records and compared between weaned and non-weaned ECMO patients. The patients were followed until June 30, 2020. Logistic regression analyses were performed to identify the risk factors associated with unsuccessful ECMO weaning. Propensity score matching was used to match patients who received veno-venous ECMO with those who received invasive mechanical ventilation (IMV)-only therapy. The primary endpoint, 120-day all-cause mortality after intensive care unit (ICU) admission during hospitalization, was compared using a mixed-effect Cox model.Results Of 88 patients who received ECMO therapy, 27 and 61 patients were and were not successfully weaned from ECMO, respectively. Additionally, 15, 15, and 65 patients were further weaned from IMV, discharged from hospital, or died during hospitalization, respectively. A lymphocyte count ≤ 0.5 × 109/L and D-dimer concentration > 4 × the upper limit of normal at ICU admission, a peak PaCO2 > 60 mmHg at 24 hours before ECMO initiation, and no tracheotomy performed during the ICU stay were independently associated with lower odds of ECMO weaning. In the propensity score-matched analysis, a mixed-effect Cox model detected a lower hazard ratio for 120-day all-cause mortality after ICU admission during hospitalization in the ECMO group, as compared with the IMV-only group.Conclusion Patients in Wuhan who received ECMO therapy had a relatively high mortality rate. This outcome may be largely attributable to resource-limited situations during the COVID-19 MESHD outbreak. In future, the presence of lymphocytopenia MESHD and higher D-dimer concentrations at ICU admission and hypercapnia HP hypercapnia MESHD at 24 hours before ECMO initiation could help to identify patients with a poor prognosis. Moreover, tracheotomy could facilitate weaning from ECMO. Despite the high mortality, ECMO was associated with improved outcomes relative to IMV-only therapy in critically ill COVID-19 MESHD patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.